亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Effect of baseline oestradiol serum concentration on the efficacy of anastrozole for preventing breast cancer in postmenopausal women at high risk: a case-control study of the IBIS-II prevention trial

医学 阿那曲唑 乳腺癌 芳香化酶抑制剂 内科学 肿瘤科 激素替代疗法(女性对男性) 妇科 性激素结合球蛋白 睾酮(贴片) 临床终点 癌症 随机对照试验 三苯氧胺 激素 雄激素
作者
Jack Cuzick,Kim Chu,Brian Keevil,Adam R. Brentnall,Anthony Howell,Nicholas Zdenkowski,Bernardo Bonanni,Sibylle Loibl,Kaija Holli,D. Gareth Evans,Steve Cummings,Mitch Dowsett
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:25 (1): 108-116 被引量:5
标识
DOI:10.1016/s1470-2045(23)00578-8
摘要

Summary

Background

An increased risk of breast cancer is associated with high serum concentrations of oestradiol and testosterone in postmenopausal women, but little is known about how these hormones affect response to endocrine therapy for breast cancer prevention or treatment. We aimed to assess the effects of serum oestradiol and testosterone concentrations on the efficacy of the aromatase inhibitor anastrozole for the prevention of breast cancer in postmenopausal women at high risk.

Methods

In this case-control study we used data from the IBIS-II prevention trial, a randomised, controlled, double-blind trial in postmenopausal women aged 40–70 years at high risk of breast cancer, conducted in 153 breast cancer treatment centres across 18 countries. In the trial, women were randomly assigned (1:1) to receive anastrozole (1 mg/day, orally) or placebo daily for 5 years. In this pre-planned case-control study, the primary analysis was the effect of the baseline oestradiol to sex hormone binding globulin (SHBG) ratio (oestradiol–SHBG ratio) on the development of all breast cancers, including ductal carcinoma in situ (the primary endpoint in the trial). Cases were participants in whom breast cancer was reported after trial entry and until the cutoff on Oct 22, 2019, and who had valid blood samples and no use of hormone replacement therapy within 3 months of trial entry or during the trial. For each case, two controls without breast cancer were selected at random, matched on treatment group, age (within 2 years), and follow-up time (at least that of the matching case). For each treatment group, we applied a multinominal logistic regression likelihood-ratio trend test to assess what change in the proportion of cases was associated with a one-quartile change in hormone ratio. Controls were used only to determine quartile cutoffs. Profile likelihood 95% CIs were used to indicate the precision of estimates. A secondary analysis also investigated the effect of the baseline testosterone–SHBG ratio on breast cancer development. We also assessed relative benefit of anastrozole versus placebo (calculated as 1 – the ratio of breast cancer cases in the anastrozole group to cases in the placebo group). The trial was registered with ISRCTN (number ISRCTN31488319) and completed recruitment on Jan 31, 2012, but long-term follow-up is ongoing.

Findings

3864 women were recruited into the trial between Feb 2, 2003, and Jan 31, 2012, and randomly assigned to receive anastrozole (n=1920) or placebo (n=1944). Median follow-up time was 131 months (IQR 106–156), during which 85 (4·4%) cases of breast cancer in the anastrozole group and 165 (8·5%) in the placebo group were identified. No data on gender, race, or ethnicity were collected. After exclusions, the case-control study included 212 participants from the anastrozole group (72 cases, 140 controls) and 416 from the placebo group (142 cases, 274 controls). A trend of increasing breast cancer risk with increasing oestradiol–SHBG ratio was found in the placebo group (trend per quartile 1·25 [95% CI 1·08 to 1·45], p=0·0033), but not in the anastrozole group (1·06 [0·86 to 1·30], p=0·60). A weaker effect was seen for the testosterone–SHBG ratio in the placebo group (trend 1·21 [1·05 to 1·41], p=0·011), but again not in the anastrozole group (trend 1·18 [0·96 to 1·46], p=0·11). A relative benefit of anastrozole was seen in quartile 2 (0·55 [95% CI 0·13 to 0·78]), quartile 3 (0·54 [0·22 to 0·74], and quartile 4 (0·56 [0·23 to 0·76]) of oestradiol–SHBG ratio, but not in quartile 1 (0·18 [–0·60 to 0·59]).

Interpretation

These results suggest that serum hormones should be measured more routinely and integrated into risk management decisions. Measuring serum hormone concentrations is inexpensive and might help clinicians differentiate which women will benefit most from an aromatase inhibitor.

Funding

Cancer Research UK, National Health and Medical Research Council (Australia), Breast Cancer Research Foundation, and DaCosta Fund.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
9秒前
lijiawei发布了新的文献求助10
11秒前
Criminology34发布了新的文献求助50
13秒前
睡觉补充能量完成签到,获得积分10
13秒前
fengfenghao完成签到,获得积分10
19秒前
小凯完成签到 ,获得积分10
22秒前
jueshadi完成签到 ,获得积分10
22秒前
朵朵完成签到,获得积分10
24秒前
29秒前
33秒前
dong发布了新的文献求助10
34秒前
36秒前
36秒前
36秒前
aaaaal发布了新的文献求助10
38秒前
40秒前
annaanna完成签到 ,获得积分10
42秒前
Criminology34发布了新的文献求助50
44秒前
ccc完成签到 ,获得积分10
44秒前
46秒前
YY发布了新的文献求助10
46秒前
Gin发布了新的文献求助10
49秒前
aaaaal完成签到,获得积分10
49秒前
Becky完成签到 ,获得积分10
52秒前
53秒前
杨北风完成签到 ,获得积分20
53秒前
科研通AI6应助科研通管家采纳,获得10
54秒前
55秒前
共享精神应助科研通管家采纳,获得10
55秒前
55秒前
所所应助科研通管家采纳,获得10
55秒前
55秒前
55秒前
Hello应助科研通管家采纳,获得10
55秒前
小蘑菇应助科研通管家采纳,获得10
55秒前
55秒前
ye发布了新的文献求助20
58秒前
59秒前
1分钟前
Abu完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Architectural Corrosion and Critical Infrastructure 1000
Early Devonian echinoderms from Victoria (Rhombifera, Blastoidea and Ophiocistioidea) 1000
By R. Scott Kretchmar - Practical Philosophy of Sport and Physical Activity - 2nd (second) Edition: 2nd (second) Edition 666
Electrochemistry: Volume 17 600
Physical Chemistry: How Chemistry Works 500
SOLUTIONS Adhesive restoration techniques restorative and integrated surgical procedures 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 内科学 生物化学 物理 计算机科学 纳米技术 遗传学 基因 复合材料 化学工程 物理化学 病理 催化作用 免疫学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 4944655
求助须知:如何正确求助?哪些是违规求助? 4209521
关于积分的说明 13085355
捐赠科研通 3989302
什么是DOI,文献DOI怎么找? 2184055
邀请新用户注册赠送积分活动 1199418
关于科研通互助平台的介绍 1112457